Format

Send to

Choose Destination
Ann Thorac Surg. 2019 Jul;108(1):e5-e7. doi: 10.1016/j.athoracsur.2018.11.047. Epub 2018 Dec 21.

Use of Angiotensin II for Post Cardiopulmonary Bypass Vasoplegic Syndrome.

Author information

1
Department of Anesthesiology, Morristown Medical Center, Morristown, New Jersey.
2
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
3
Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, New York.
4
Department of Surgery, Morristown Medical Center, Morristown, New Jersey.
5
Division of Critical Care Medicine, Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: jchow@som.umaryland.edu.

Abstract

Angiotensin II is a novel vasopressor recently approved for the treatment of vasodilatory shock. We describe a case in which Angiotensin II was used to treat post-cardiopulmonary bypass vasoplegic syndrome in a patient who was refractory to standard vasopressors and other rescue therapies. Despite requiring high-dose vasopressors, the patient was extubated within 24 hours and has met key quality metrics defined by The Society of Thoracic Surgeons.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center